The US consumer health product sector’s first results from the latest quarter could indicate the start of the strongest period in a decade for OTC cough/cold product sales, analysts at Raymond James suggest.
Increasing numbers for sales of Rx cough/cold drugs combined with an apparent waning interest by consumers in receiving flu vaccines point to the 2022-2023 season rivaling the decade-high levels from 2017-18 and to retailers boosting their inventories through year-end, stated Elliot Wilbur and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?